Istituto di Neuroscienze del Prof. Stefano Pallanti

What Istituto di Neuroscienze del Prof. Stefano Pallanti does

Istituto di Neuroscienze del Prof. Stefano Pallanti is a private Italian clinical neuroscience center founded in 1989 in Florence by Prof. Stefano Pallanti, a physician-neuroscientist with academic appointments at Albert Einstein School of Medicine, Icahn School of Medicine at Mount Sinai, and Imperial College London. The institute specializes in precision psychiatry for treatment-resistant and complex mental health conditions, applying the proprietary "Pallanti Method" — a translational clinical framework that integrates European phenomenological tradition with US evidence-based methodology and uses the Research Domain Criteria (RDoC) framework to diagnose brain circuit dysfunctions beyond behavioral classification.

The service portfolio spans neuromodulation therapies (rTMS, Theta-Burst TMS, tDCS, Photo-Bio-Modulation, VNS, Light Therapy, Neurofeedback), pharmacological treatments (including Ketamine/Esketamine for treatment-resistant depression, IV infusions, and off-label SSRI use), psychotherapy (CBT/EMDR), mindfulness, and pharma-standard supplements. Diagnostics include Level II and III evaluations using psychometric tools, EEG, ECG, PET, MRI, genetic tests, metabolic and immunological markers, and gut screening. The institute has been a serial early adopter of neuromodulation modalities, deploying rTMS and tDCS in 2005 — three years before FDA approval — and currently runs 12 active research projects including NIMH and EU Horizon grants.

The business model is fully self-pay with no Italian National Health Service (SSN) or insurance affiliations: revenue is generated from individual patient visits, neuromodulation treatment cycles, IV therapy, telemedicine (via Skype since 2008), corporate/professional services (clinical studies, hospital program development, sports neuroscience consulting), and training courses (TMS certification, ECM programs). The institute operates from Florence, Bologna, Milan, and New Delhi, treats over 10,000 patients per year, and has served over 1,500 telemedicine patients since 2008. It is legally organized as Centro di Neurologia, Psichiatria e Psicologia Clinica S.r.l., a private Italian limited liability company, founder-owned with no disclosed institutional investment.

Name

Istituto di Neuroscienze del Prof. Stefano Pallanti

Legal name

Centro di Neurologia, Psichiatria e Psicologia Clinica S.r.l.

Website

https://istitutodineuroscienze.it

Company type

Private

Founded year

1989

Operating status

Operating

Headcount range

11–50 employees

Short description

Istituto di Neuroscienze del Prof. Stefano Pallanti is a private Italian clinical neuroscience center founded in 1989 in Florence, delivering self-pay precision psychiatry, neuromodulation (TMS, tDCS, VNS, Ketamine), and Level II/III diagnostics to patients with treatment-resistant mental health conditions across Florence, Bologna, Milan, and New Delhi.

Ownership category

akta.pro rank

Product category

Neuroscience Clinical Services

NAICS

Offices of Physicians, Mental Health Specialists (621112), Outpatient Mental Health and Substance Abuse Centers (621420)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011)

akta.pro primary industry

Outpatient Mental Health Clinics & Counseling Centers (HLAFACAA)

akta.pro secondary industries

Psychiatry & Medication Management Platforms (HLALAEAB), Outpatient Mental Health & Counseling Clinics (HLAFABAC)

Keywords

• Neuromodulation therapies
• Precision psychiatry services
• Transcranial magnetic stimulation
• Treatment-resistant depression
• Clinical neuroscience treatments

Headquarters

HQ city

Florence

HQ country

Italy

HQ region

Europe

Offices4 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Clinical Services - Patient Visits: Direct patient payments for specialist psychiatric consultations, diagnostic evaluations, and follow-up visits. The institute is a private center without Italian National Health Service (SSN) or insurance affiliations, meaning all services are paid directly by patients.
2. Neuromodulation Therapy: Revenue from TMS, tDCS, Photo-Bio-Modulation, VNS, Light Therapy, and related neuromodulation treatment cycles. Typically delivered as consecutive day protocols lasting 30-60 days for initial cycles.
3. IV Therapy and Pharmaceutical Treatments: Revenue from intravenous therapies and pharmacological treatments including Ketamine infusions, Esketamine spray, and other pharmaceutical interventions.
4. Remote Consultations: Telemedicine services via Skype, available since 2008, serving patients throughout Italy and internationally.
5. Corporate/Professional Services: Services for companies including clinical studies, precision diagnosis program development for hospitals, care project development, product growth strategies for pharmaceutical/biotech companies, and sports neuroscience consulting.
6. Training Courses: Education and training services for healthcare providers including TMS certification, internships, conferences, and ECM (Continuing Medical Education) courses.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels8 records

Core offering

The institute provides specialized private-pay psychiatric and neuroscience-based clinical care, including neuromodulation therapies (rTMS, tDCS, Theta-Burst, VNS, Photo-Bio-Modulation, Neurofeedback, Light Therapy), advanced pharmacological treatments (Ketamine/Esketamine for treatment-resistant depression, off-label medications, IV infusions), psychotherapy (CBT, EMDR), mindfulness programs, pharma-standard supplements, and Level II/III precision diagnostics (EEG, PET, MRI, genetic, metabolic, immunological, gut-screening). Care is delivered through in-person clinic visits in Florence, Bologna, and Milan, international branch in New Delhi, and Skype-based telemedicine since 2008.

Product overview

Istituto di Neuroscienze is a private clinical neuroscience center founded in 1989 by Prof. Stefano Pallanti, offering a unified platform of precision psychiatry services centered on The Pallanti Method. The portfolio comprises neuromodulation therapies (TMS, tDCS, Photo-Bio-Modulation, VNS, Neurofeedback, Light Therapy), pharmacological therapy (including off-label treatments, Esketamine/Ketamine for resistant depression), psychotherapy (CBT/EMDR), IV therapy, and pharma-standard supplements. Treatment programs span ADHD, anxiety, depression, OCD, autism, gambling disorder, and other conditions. The institute provides Level II and III precision diagnostics using EEG, PET, MRI, genetic tests, and metabolic evaluations, combined with telemedicine via Skype. Services extend to professional training and corporate wellness programs.

Differentiator

Problem solved

Functional benefit

Products and services

• Transcranial Magnetic Stimulation (TMS) Neuromodulation therapy using magnetic fields to stimulate nerve cells in the brain. Offered as rTMS, Theta-Burst TMS, and Deep TMS protocols. Typically delivered as 30-60 consecutive day initial cycles depending on clinical condition.
• Ketamine Clinic Ketamine and Esketamine therapy for treatment-resistant depression, considered life-saving for patients who have not responded to other treatments.
• IV Therapy (Terapia Endovenosa Infusionale) Intravenous therapy for depression, OCD, anxiety, and cognitive disorders using infusions of Ketamine, Citalopram, Clomipramine, Ademetionine, N-Acetylcysteine, Sodium Valproate, Levosulpiride, Tiapride, and Secretin.
• Photo-Bio-Modulation Neuromodulation therapy using light to modulate brain activity, introduced in 2019.
• Neurofeedback Non-invasive neuromodulation technique enabling patients to learn self-regulation of brain activity, applied to ADHD treatment.
• Vagus Nerve Stimulation (VNS) Non-invasive neuromodulation of the vagus nerve introduced in 2020 for various neurological and psychiatric conditions.
• tDCS (Transcranial Direct Current Stimulation) Non-invasive brain stimulation technique using low electrical currents, offered since 2005 for various psychiatric and neurological conditions.
• Light Therapy Therapeutic light-based neuromodulation introduced in 2001 for various psychiatric conditions.
• Pharmacological Therapy Evidence-based pharmacological treatments including off-label medications aligned with the latest international scientific evidence.
• Psychotherapy (CBT-EMDR) Cognitive Behavioral Therapy and EMDR approaches integrated with neuroscientific evidence for comprehensive mental health treatment.
• Mindfulness Programs Mindfulness practices combined with neuromodulation therapies since 2020, offered since 2012 through Master Course programs.
• Pharma-standard Supplements Pharmaceutical-grade nutritional supplements introduced in 2010 for holistic treatment approaches.
• Precision Diagnosis (Level II and III) Neuroscientific diagnostic services including psychometric assessments, neurofunctional evaluations (EEG, QEEG, ECG, P300, PET, MRI), genetic tests, blood tests, metabolic and immunological evaluations, and gut-screening for precise diagnosis beyond behavioral classification.
• Telemedicine (Remote Skype Visits) Remote clinical consultations via Skype, pioneered since 2008, serving over 1,500 patients from Italy and abroad.
• ADHD Treatment Program Life-span ADHD program for children and adults including specialized diagnosis and multimodal treatment approaches including neuromodulation, pharmacotherapy, and Neurofeedback.
• Anxiety and Anxiety Disorders Treatment Expert treatment for anxiety disorders using neuromodulation therapies (pioneers since 2005), pharmacotherapy, and psychotherapy.
• Depression Treatment Individualized neuroscience-based diagnosis and integrated treatment approaches for depression subtypes and comorbid disorders, including Ketamine/Esketamine for treatment-resistant cases.
• OCD and Obsessive-Compulsive Spectrum Disorders Treatment Integrated treatment combining neuromodulation, pharmacological therapy, psychotherapy, and natural therapies for OCD spectrum disorders.
• Gambling Disorder Treatment Personalized treatment programs integrating psychological support, pharmacological therapy, and neuromodulation (TMS Theta-Burst), developed in collaboration with Harvard University.
• Autism Treatment Treatment for neuro-immune diversity conditions, addressing dysfunctions through personalized therapeutic approaches.
• Professional Training Courses Training courses for healthcare providers on TMS services for substance and behavioral addictions, CME courses, conferences, and internships.
• Services for Companies (Corporate/Professional Services) Clinical studies, scientific research, precision diagnosis programs for hospitals, cutting-edge care projects, pharmaceutical product strategies, sports neuroscience, and stress/suicide prevention programs.

Quantifiable outcome

• Over 10,000 patients treated annually
• +2 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability2 records

Feature6 records

Partnerships

Three partnerships are on record, tiered core and minor.

• International College of Neuropsychopharmacology (CINP)coreStrategic or Co-development Partner · 1 January 2026Dr. Pallanti serves as Chair of the Global Network Communities on Neuromodulation within CINP. The network aims to create collaborative environments for professionals with shared specialist interests, develop joint research projects, pursue educational objectives, promote new therapeutic modalities, and develop symposium proposals for the annual CINP World Congress. Members include Joan Camprodon (USA), Risto Ilmoniemi (Finland), Giovanni Martinotti (Italy), Valerie Voon (UK), Abraham Zangen (Israel), and Odile Van Den Heuvel (The Netherlands).
• Harvard UniversitycoreStrategic or Co-development Partner · 1 January 2017Collaboration with Harvard University for TMS (Transcranial Magnetic Stimulation) research in behavioral addiction. The institute introduced TMS for behavioral addiction in 2017 in collaboration with Harvard.
• Maastricht UniversityminorStrategic or Co-development PartnerCollaboration with Maastricht University for the Summer School on Affective Neuroscience, scheduled for July 2, 2026 at the University of Florence. Prof. Pallanti delivers lectures on TMS for behavioral addiction.

Scale indicators5 records

Recent moves7 records

Expansion highlights7 records

Broad incumbents

• Priory Group: UK-based leading independent provider of mental health, addiction, and neuro-rehabilitation services across inpatient and outpatient settings. Comparable patient populations in depression, OCD, and addiction but at much broader scale and with insurance/referral-based access.
• Schoen Clinic Group: One of Germany's largest private hospital groups with a strong specialty in psychiatry, psychosomatics, and behavioral disorders. Broader scale and inpatient depth, but overlapping treatment scope in complex psychiatric care, including TMS and multimodal therapies.
• Charité Department of Psychiatry: One of Europe's largest academic psychiatry departments at Charité Universitätsmedizin Berlin, offering specialized neuromodulation, addiction, OCD, and treatment-resistant depression programs. Comparable clinical scope but embedded within a public academic hospital with research scale the institute cannot match.

Direct peers

• Paracelsus Recovery: Zurich-based private mental health clinic treating depression, burnout, trauma, and addiction with a one-client-at-a-time residential and outpatient model. Comparable specialist psychiatry positioning, neuroscience-informed treatment, and self-pay European clientele.
• The Kusnacht Practice: Swiss private mental health clinic offering individualized treatment for depression, anxiety, OCD, and addiction in a luxury, single-fee-per-day model. Directly comparable boutique outpatient psychiatry model with high-end self-pay clientele and neuroscience-based treatment philosophy.
• Klinik Alysia: Italian private psychiatric clinic in Bavaria offering specialized treatment for depression, anxiety, and addiction. Comparable European specialist psychiatry operator with a focus on individualized, multimodal, neuroscience-informed care.

Others

• Neuronetics: US-listed developer and manufacturer of NeuroStar TMS systems for major depressive disorder. Comparable through its role as a leading TMS device vendor whose installed base drives clinical TMS adoption, complementing and competing with the institute's clinical practice model.
• Magstim: UK-based manufacturer of TMS stimulator systems widely used in research and clinical psychiatry. Ecosystem partner enabling neuromodulation clinics like the institute; comparable through its central role in the TMS equipment market underpinning rTMS, Theta-Burst, and SNT protocols.

Emerging players

• Brainclinics Foundation: Netherlands-based clinical and research organization specializing in non-invasive brain stimulation (TMS, tDCS) and neurofeedback for psychiatric and neurological disorders. Highly comparable neuromodulation focus, with overlapping RDoC-style precision psychiatry philosophy.

Regional players

• Clinica Privata Villalba (Gruppo San Donato): Italian private psychiatric and rehabilitation clinic within the Gruppo San Donato network offering specialized inpatient and outpatient mental health services. Comparable Italian private specialist psychiatry competitor serving similar self-pay and insured patient segments.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/spallanti
• YouTubeyoutube.com/user/stefanopallanti
• Facebookfacebook.com/stefanopallanti
• LinkedInlinkedin.com/company/istituto-di-neuroscienze
• Instagraminstagram.com/istitutodineuroscienze

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Istituto di Neuroscienze del Prof. Stefano Pallanti